NeuroSense Therapeutics Ltd. Files August 2025 6-K Report
Ticker: NRSNW · Form: 6-K · Filed: Aug 21, 2025 · CIK: 1875091
Sentiment: neutral
Topics: foreign-private-issuer, routine-filing, sec-filing
Related Tickers: NRSN
TL;DR
NeuroSense (NRSN) filed its monthly 6-K report on 8/21/25, confirming it's a foreign private issuer filing 20-F.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on August 21, 2025, reporting information for the month of August 2025. The company, based in Herzliya, Israel, is a pharmaceutical preparations company and will file its annual reports under Form 20-F. This filing is a routine report of a foreign private issuer.
Why It Matters
This filing provides routine updates for investors and stakeholders regarding NeuroSense Therapeutics Ltd.'s status as a foreign private issuer. It confirms their reporting schedule and location.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would typically increase risk.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- August 2025 (date) — Reporting period
- 20250821 (date) — Filing date
- 001-41084 (other) — SEC file number
- Herzliya, Israel (location) — Company headquarters
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC if they are required to disclose or distribute information to their security holders pursuant to the laws of their home country.
What is NeuroSense Therapeutics Ltd.'s standard industrial classification?
NeuroSense Therapeutics Ltd.'s standard industrial classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Which form will NeuroSense Therapeutics Ltd. use for its annual reports?
NeuroSense Therapeutics Ltd. will file its annual reports under cover of Form 20-F.
Where is NeuroSense Therapeutics Ltd. located?
NeuroSense Therapeutics Ltd.'s principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
What is the filing date of this specific Form 6-K?
This specific Form 6-K was filed on August 21, 2025.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2025-08-21 16:56:04
Filing Documents
- ea025405001-6k_neuro.htm (6-K) — 27KB
- ea025405001ex99-1_neuro.htm (EX-99.1) — 76KB
- ea025405001ex99-2_neuro.htm (EX-99.2) — 8KB
- tneurosense_logo.jpg (GRAPHIC) — 123KB
- tneurosense_logo1.jpg (GRAPHIC) — 123KB
- tproxy_001.jpg (GRAPHIC) — 1192KB
- tproxy_002.jpg (GRAPHIC) — 724KB
- 0001213900-25-079411.txt ( ) — 3093KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   NeuroSense Therapeutics Ltd. Date: August 21, 2025   By:   /s/ Alon Ben-Noon         Alon Ben -Noon         Chief Executive Officer 2